| Real-world Data of Nivolumab in Pre-treated NSCLC (NCT04713462) | Hellenic Cooperative Oncology Group | 2015-10-01 |
| Liquid Biopsy for Detection of Driver Mutation in NSCLC (NCT02778854) | Chinese PLA General Hospital | 2015-10-01 |
| Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET (NCT02544633) | Mirati Therapeutics Inc. | 2015-10-01 |
| A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC (NCT02463994) | University of Michigan Rogel Cancer Center | 2015-10-01 |
| A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer (NCT02543645) | Celldex Therapeutics | 2015-10-01 |
| Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer (NCT02580708) | Clovis Oncology, Inc. | 2015-09-30 |
| A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification (NCT02468661) | Novartis Pharmaceuticals | 2015-09-23 |
| Genomic Landscape of Ceritinib (NCT02554591) | Washington University School of Medicine | 2015-09-16 |
| SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer (NCT02562027) | Washington University School of Medicine | 2015-09-11 |
| Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (NCT02526017) | Five Prime Therapeutics, Inc. | 2015-09-08 |
| A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI) (NCT02495233) | Astellas Pharma Global Development, Inc. | 2015-09-08 |
| An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer). (NCT02321046) | AstraZeneca | 2015-09-02 |
| An Observational Research Of Crizotinib's Hepatic Toxicity In Non-small Cell Lung Cancer Patients (NCT02708667) | Sun Yat-sen University | 2015-09-01 |
| Safety Study of MGD009 in B7-H3-expressing Tumors (NCT02628535) | MacroGenics | 2015-09-01 |
| Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC (NCT02577627) | Optimata Ltd. | 2015-09-01 |
| Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations (NCT02277457) | University of Michigan Rogel Cancer Center | 2015-09-01 |
| Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC (NCT03780010) | Tracon Pharmaceuticals Inc. | 2015-09-01 |
| Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung (NCT02485652) | Hanmi Pharmaceutical Company Limited | 2015-08-31 |
| Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC) (NCT02437136) | Syndax Pharmaceuticals | 2015-08-26 |
| LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib. (NCT02450903) | Novartis Pharmaceuticals | 2015-08-21 |
| Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer (NCT02577341) | Sun Yat-sen University | 2015-08-01 |
| Study of Split-course Chemoradiotherapy For Locally Advanced None-small Cell Lung Cancer (NCT02573506) | Sun Yat-sen University | 2015-08-01 |
| Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib (NCT02538627) | Merrimack Pharmaceuticals | 2015-08-01 |
| Study of Split-course Chemoradiotherapy For Postoperative Locoregional Recurrence Of Non-small Cell Lung Cancer (NCT03006575) | Sun Yat-sen University | 2015-08-01 |
| A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer (NCT02443324) | Eli Lilly and Company | 2015-07-29 |
| A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors (NCT02452424) | Daiichi Sankyo | 2015-07-02 |
| Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC (NCT02492568) | The Netherlands Cancer Institute | 2015-07-01 |
| Study of Stereotactic Ablative Radiotherapy (SABR) in Elderly Stage I NSCLC (NCT02584699) | Luhua Wang | 2015-07-01 |
| JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer (NCT02468024) | University of Texas Southwestern Medical Center | 2015-07-01 |
| Comparison of Lobectomy and Segmentectomy for cT1aN0M0 Peripheral NSCLC (NCT02481661) | Zhejiang Cancer Hospital | 2015-07-01 |
| Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer (NCT02475213) | MacroGenics | 2015-07-01 |
| Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer (NCT02495636) | Yale University | 2015-07-01 |
| Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers (NCT02349412) | Alliance for Clinical Trials in Oncology | 2015-06-25 |
| Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific (NCT02442349) | AstraZeneca | 2015-06-22 |
| Afatinib Genomic Landscape (NCT02491775) | Washington University School of Medicine | 2015-06-11 |
| Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation (NCT02448797) | Betta Pharmaceuticals Co., Ltd. | 2015-06-08 |
| Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC (NCT02382406) | Nisha Mohindra, MD | 2015-06-04 |
| Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC (NCT02109653) | Array Biopharma, now a wholly owned subsidiary of Pfizer | 2015-06-01 |
| Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC (NCT05862194) | Yuhan Corporation | 2015-06-01 |
| TAURAS - T790 AURA ScreenFailure SOC Registry Study (NCT02405247) | AstraZeneca | 2015-06-01 |
| A Retrospective Study About Treatment Strategy After First/Second Line EGFR-TKI Failure (NCT02618590) | Sun Yat-sen University | 2015-06-01 |
| Comparative Study of the Hypoxia Measured in FAZA and F-miso PET/CT Scan in Patients With Non-small Cell Lung Cancer (NCT02490696) | Centre Henri Becquerel | 2015-06-01 |
| Neoadjuvant Itraconazole in Non-small Cell Lung Cancer (NCT02357836) | University of Texas Southwestern Medical Center | 2015-06-01 |
| Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients (NCT02454842) | Rain Oncology Inc | 2015-06-01 |
| T790M Mutation Positive 2nd Line STandard of cAre Registry (NCT02368990) | AstraZeneca | 2015-06-01 |
| Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC (NCT02337530) | Canadian Cancer Trials Group | 2015-05-26 |
| Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI) (NCT02342353) | Washington University School of Medicine | 2015-05-18 |
| Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) (NCT02349633) | Pfizer | 2015-05-14 |
| Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer. (NCT02292550) | Novartis Pharmaceuticals | 2015-05-14 |
| National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer (NCT02664935) | University of Birmingham | 2015-05-13 |
| Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NCT02299141) | Washington University School of Medicine | 2015-05-07 |
| A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111) (NCT02409355) | Hoffmann-La Roche | 2015-05-07 |
| Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer (NCT02448251) | ACEA Therapeutics, Inc. | 2015-05-01 |
| Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC (NCT02455843) | Shandong Provincial Hospital | 2015-05-01 |
| Micro RNA Genetic Signature in NSCLC Egyptian Patients (NCT02445924) | Adel Salah Bediwy | 2015-05-01 |
| Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression (NCT02431169) | Washington University School of Medicine | 2015-04-30 |
| An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC (NCT02409368) | Bristol-Myers Squibb | 2015-04-29 |
| Pazopanib in Molecularly Selected Patients With Advanced NSCLC (NCT02193152) | Washington University School of Medicine | 2015-04-27 |
| Safety Study of AMG 228 to Treat Solid Tumors (NCT02437916) | Amgen | 2015-04-21 |
| A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC (NCT02309892) | Helix BioPharma Corporation | 2015-04-20 |
| A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain (NCT02308020) | Eli Lilly and Company | 2015-04-20 |
| A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer (NCT02424617) | BerGenBio ASA | 2015-04-19 |
| A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (NCT02439450) | Heat Biologics | 2015-04-15 |
| A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer (NCT02391480) | AbbVie | 2015-04-14 |
| Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) (NCT02299505) | Novartis Pharmaceuticals | 2015-04-09 |
| Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC (NCT02353741) | Xinqiao Hospital of Chongqing | 2015-04-01 |
| A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC (NCT02364999) | Pfizer | 2015-04-01 |
| A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC (NCT02374645) | Hutchison Medipharma Limited | 2015-04-01 |
| Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) (NCT02423954) | Western Regional Medical Center | 2015-04-01 |
| Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy (NCT02407600) | Ajeet Gajra | 2015-04-01 |
| Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects (NCT02284139) | Dong-A University Hospital | 2015-04-01 |
| Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer (NCT02381314) | MacroGenics | 2015-03-26 |
| The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib (NCT04640870) | Hellenic Cooperative Oncology Group | 2015-03-15 |
| Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC. (NCT02405910) | West Virginia University | 2015-03-15 |
| Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer (NCT02317016) | AstraZeneca | 2015-03-10 |
| Study of S-588410 After Adjuvant Chemotherapy for Completely Resected Non-small- Cell Lung Cancer (NCT02410369) | Tokyo University | 2015-03-01 |
| Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy (NCT02444819) | Hanmi Pharmaceutical Company Limited | 2015-03-01 |
| A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors (NCT02403271) | Pharmacyclics LLC. | 2015-03-01 |
| Comparison of Cost-effectiveness of Continuation Maintenance Therapy With Six Cycles of Pemetrexed Versus Pemetrexed Until Disease Progression for Metastatic Non-squamous Non-small-cell Lung Cancer (NCT02397239) | National Cheng-Kung University Hospital | 2015-03-01 |
| Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer (NCT02274038) | University of Pennsylvania | 2015-03-01 |
| Safety Study of SEA-CD40 in Cancer Patients (NCT02376699) | Seagen Inc. | 2015-02-28 |
| Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303） (NCT02388919) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2015-02-26 |
| Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC (NCT02273375) | Canadian Cancer Trials Group | 2015-02-24 |
| The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation (NCT03399669) | Samsung Medical Center | 2015-02-17 |
| Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer (NCT02323126) | Novartis Pharmaceuticals | 2015-02-09 |
| Evaluation of Gender Differences on the Psychosocial and Economic Impact in Patients With Advanced Non-small Cell Lung Cancer (NCT02336061) | Asociación para la Investigación del Cáncer de Pulmón en Mujeres | 2015-02-03 |
| A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma (NCT02347917) | Sumitomo Pharma Co., Ltd. | 2015-02-01 |
| Therapeutic Resistance Prediction of Tyrosine Kinase Inhibitors (NCT02851329) | Chinese Academy of Sciences | 2015-02-01 |
| National Comprehensive Cancer Network (NCCN) Decision Support Tool for Patients With NSCLC (NCT03982459) | University of California, San Francisco | 2015-02-01 |
| TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy (NCT02322281) | Clovis Oncology, Inc. | 2015-02-01 |
| Combined Effect of Natural Killer Cell and Doublet Chemotherapy in Advanced NSCLC as the 1st Line Treatment (NCT02370017) | The Catholic University of Korea | 2015-02-01 |
| A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC (NCT02387216) | Elevation Oncology | 2015-02-01 |
| Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa (NCT02304406) | Pfizer | 2015-01-21 |
| Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. (NCT02335944) | Novartis Pharmaceuticals | 2015-01-13 |
| A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor (NCT02365662) | AbbVie | 2015-01-09 |
| Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer (NCT02358473) | Kyowa Kirin, Inc. | 2015-01-01 |
| Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer (NCT02535507) | Tongji University | 2015-01-01 |
| Study of Apatinib in RET Fusion Positive Advanced Non-small Cell Lung Cancer (NCT02540824) | Tongji University | 2015-01-01 |
| Circulating Tumor DNA Exposure in Peripheral Blood (NCT03517332) | Quantgene Inc. | 2015-01-01 |
| The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer (NCT02515435) | Tongji University | 2015-01-01 |